Compare TG Therapeutics Inc (TGTX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 8.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| TGTX | VNQ | |
|---|---|---|
Market Cap | $8.16B | $70.80B |
Volume | 1,735,121 | 6,073,580 |
Sector | Health | — |
52-Week High | $59.06 | $100.95 |
52-Week Low | $26.94 | $87.00 |
Typical Hold Time | 16 Days | 113 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
VNQ trades at $90.65, up 2.21% today, but faces bearish technical signals with 14 sell indicators versus 5 buys. The ETF has declined nearly 10% in the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector-wide REIT pressures and dividend yield comparisons with Treasury bills.
Outlook remains cautious with technical weakness and interest rate sensitivity posing near-term risks. However, contrarian investors may find opportunity in the sector sell-off if long-term real estate fundamentals hold. Key risks include further rate hikes and economic slowdowns affecting property valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
